elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (Genvoya) -

elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (Genvoya)
Information type: Guidance
Source: Scottish Medicines Consortium
Specialities: Infection and infectious diseases
Summary
The SMC has accepted for use within NHS Scotland, Genvoya® for the treatment of adults and adolescents (aged >12 years with body weight >35kg) with HIV-1 without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.
UKMi comment
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of Genvoya®, and is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Related links: